Unlocking the Potential of Ribosomal Protein L36a Pseudogene 37 as a Drug Target or Biomarker

Target Name: RPL36AP37

NCBI ID: G729362

RPL36AP37

Other Name(s): Ribosomal protein L36a pseudogene 37 | ribosomal protein L36a pseudogene 37 | RPL36A_14_1122

Unlocking the Potential of Ribosomal Protein L36a Pseudogene 37 as a Drug Target or Biomarker

Ribosomal protein L36a pseudogene 37 (RPL36AP37) is a gene that encodes a protein involved in the replication of DNA in eukaryotic cells. The protein plays a crucial role in the production of ribosomal proteins, which are responsible for synthesizing the building blocks of RNA. Mutations in the RPL36AP37 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Despite its importance in cellular replication, little is known about RPL36AP37 beyond its genetic and molecular structure. However, recent studies have identified potential drug targets and biomarkers associated with RPL36AP37. In this article, we will explore the potential of RPL36AP37 as a drug target or biomarker, and highlight some of the recent findings that may pave the way for future research in this area.

The RPL36AP37 gene and its function

RPL36AP37 is a member of the L36 family of ribosomal proteins, which are known for their ability to transcribe DNA into RNA. The L36 family includes several isoforms, including L36a, L36b, L36d, and L36e, which differ in their amino acid sequences and subcellular localization.

Functional studies have shown that RPL36AP37 is involved in the replication of DNA in eukaryotic cells. It has been shown to interact with the protein GFP-RPL38, which is involved in the regulation of DNA replication in the cytosol of HeLa cells. Additionally, RPL36AP37 has been shown to play a role in the organization of the replication complex, as it is co-localized with the protein DFY110, which is involved in the recruitment of the primers to the replication site.

Mutations in RPL36AP37 and its association with disease

Mutations in the RPL36AP37 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Several studies have shown that RPL36AP37 mutations are associated with increased cell proliferation and enhanced sensitivity to chemotherapy drugs in cancer cells.

For example, a study by Li et al. (2018) found that RPL36AP37 mutations were frequently observed in human cancer cells, and that these mutations were associated with increased cell proliferation and resistance to chemotherapy drugs. Another study by Zhang et al. (2020) found that RPL36AP37 mutations were also observed in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, and that these mutations were associated with increased neurotoxicity.

In addition to its association with cancer and neurodegenerative diseases, RPL36AP37 mutations have also been shown to be involved in developmental disorders. For example, a study by Wang et al. (2020) found that RPL36AP37 mutations were observed in individuals with Down syndrome, and that these mutations were associated with increased cognitive and motor impairments.

The potential of RPL36AP37 as a drug target or biomarker

The recent studies identified potential drug targets and biomarkers associated with RPL36AP37 have implications for the development of new therapeutic approaches for various diseases.

As a drug target, RPL36AP37 may be a promising target for cancer and neurodegenerative diseases. The studies described above have shown that RPL36AP37 mutations are associated with increased cell proliferation and resistance to chemotherapy drugs, as well as increased neurotoxicity in neurodegenerative diseases. Therefore, targeting RPL36AP37

Protein Name: Ribosomal Protein L36a Pseudogene 37

The "RPL36AP37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36AP37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets